AG-TRAZODONE 150 MG
TRAZODONE HYDROCHLORIDE : 150 MG · DIN 02537923 · ANGITA PHARMA INC.
Health Canada status: MARKETED
What is AG-TRAZODONE?
AG-TRAZODONE 150 MG contains TRAZODONE HYDROCHLORIDE : 150 MG. It is listed in the Health Canada Drug Product Database under DIN 02537923, held by ANGITA PHARMA INC., supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 23-Apr-2024. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is AG-TRAZODONE used for?
Symptomatic relief of depressive illness.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02537923 |
|---|---|
| Brand name | AG-TRAZODONE |
| Generic / active ingredient | TRAZODONE HYDROCHLORIDE : 150 MG |
| Manufacturer | ANGITA PHARMA INC. |
| Strength | 150 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | N06AX05 TRAZODONE |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 23-Apr-2024 |
How is it administered?
Initial: 150-200 mg/day in divided doses after meals. Increase by 50 mg increments up to 300 mg/day. Max 400 mg/day (600 mg for hospitalized). Elderly: Use half adult dose.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store at controlled room temperature 15°C to 30°C. Protect from light.
How is it supplied?
HDPE bottles of 30, 100, and 500 tablets.
Contraindications
Known hypersensitivity to trazodone.
Warnings and precautions
Risk of priapism (may require surgery); arrhythmogenic potential in cardiac patients; not for use during recovery from MI; risk of angle-closure glaucoma; suicide risk in depressed patients.
Is TRAZODONE in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Active — reported by SANIS HEALTH INC (Tier 3 Drug Shortages About & Resources), last seen 19 Aug 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code N06AX05 TRAZODONE. 21 of 57 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AG-TRAZODONE | 100 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02537915 |
| AG-TRAZODONE | 50 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02537907 |
| APO-TRAZODONE D TABLETS 150MG | 150 MG | TABLET | APOTEX INC | MARKETED | DIN 02147653 |
| APO-TRAZODONE TABLETS 100MG | 100 MG | TABLET | APOTEX INC | MARKETED | DIN 02147645 |
| APO-TRAZODONE TABLETS 50MG | 50 MG | TABLET | APOTEX INC | MARKETED | DIN 02147637 |
| JAMP TRAZODONE | 100 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02442817 |
| JAMP TRAZODONE | 150 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02442825 |
| JAMP TRAZODONE | 50 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02442809 |
| PMS TRAZODONE HCL TAB 100MG | 100 MG | TABLET | PHARMASCIENCE INC | MARKETED | DIN 01937235 |
| PMS TRAZODONE HCL TAB 50MG | Strength | Tablet | PHARMASCIENCE INC 100 6111 Royalmount Ave Montreal Quebec Canada H4P 2T4 | MARKETED | DIN 01937227 |
Who else supplies TRAZODONE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. TRAZODONE appears in 36 registered pack listings across 9 markets, published on 7 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.